Time to Treatment Prediction in Chronic Lymphocytic Leukemia Based on New Transcriptional Patterns

被引:7
|
作者
Mosquera Orgueira, Adrian [1 ,2 ,3 ]
Antelo Rodriguez, Beatriz [1 ,2 ,3 ]
Alonso Vence, Natalia [1 ,2 ]
Bendana Lopez, Angeles [1 ,2 ]
Diaz Arias, Jose Angel [1 ,2 ]
Diaz Varela, Nicolas [2 ]
Gonzalez Perez, Marta Sonia [1 ,2 ]
Perez Encinas, Manuel Mateo [1 ,3 ]
Bello Lopez, Jose Luis [1 ,2 ,3 ]
机构
[1] Hlth Res Inst Santiago de Compostela IDIS, Santiago De Compostela, Spain
[2] Complexo Hosp Univ Santiago de Compostela, Div Hematol, SERGAS, Santiago De Compostela, Spain
[3] Univ Santiago de Compostela, Dept Med, Santiago De Compostela, Spain
来源
FRONTIERS IN ONCOLOGY | 2019年 / 9卷
基金
日本学术振兴会;
关键词
chronic lymphocytic leukemia; time to treatment prediction; gene expression; RNAseq; machine learning; prognostic factors; IGHV; LYMPHOMA;
D O I
10.3389/fonc.2019.00079
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Chronic lymphocytic leukemia (CLL) is the most frequent lymphoproliferative syndrome in western countries. CLL evolution is frequently indolent, and treatment is mostly reserved for those patients with signs or symptoms of disease progression. In this work, we used RNA sequencing data from the International Cancer Genome Consortium CLL cohort to determine new gene expression patterns that correlate with clinical evolution.We determined that a 290-gene expression signature, in addition to immunoglobulin heavy chain variable region (IGHV) mutation status, stratifies patients into four groups with notably different time to first treatment. This finding was confirmed in an independent cohort. Similarly, we present a machine learning algorithm that predicts the need for treatment within the first 5 years following diagnosis using expression data from 2,198 genes. This predictor achieved 90% precision and 89% accuracy when classifying independent CLL cases. Our findings indicate that CLL progression risk largely correlates with particular transcriptomic patterns and paves the way for the identification of high-risk patients who might benefit from prompt therapy following diagnosis.
引用
收藏
页数:8
相关论文
共 50 条
  • [21] Current concepts in diagnosis and treatment of chronic lymphocytic leukemia
    Hus, Iwona
    Rolinski, Jacek
    WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY, 2015, 19 (05): : 361 - 367
  • [22] Venetoclax in the treatment of chronic lymphocytic leukemia
    Korycka-Wolowiec, Anna
    Wolowiec, Dariusz
    Kubiak-Mlonka, Aleksandra
    Robak, Tadeusz
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2019, 15 (05) : 353 - 366
  • [23] Duvelisib for the treatment of chronic lymphocytic leukemia
    Frustaci, Anna Maria
    Tedeschi, Alessandra
    Deodato, Marina
    Zamprogna, Giulia
    Cairoli, Roberto
    Montillo, Marco
    EXPERT OPINION ON PHARMACOTHERAPY, 2020, 21 (11) : 1299 - 1309
  • [24] Advances in the treatment of chronic lymphocytic leukemia
    Lamanna N.
    Current Hematologic Malignancy Reports, 2006, 1 (1) : 43 - 48
  • [25] Treatment options in chronic lymphocytic leukemia
    Montserrat, E
    HEMATOLOGY JOURNAL, 2004, 5 : S2 - S9
  • [26] Zanubrutinib for the treatment of chronic lymphocytic leukemia
    Bruzzese, Antonella
    Martino, Enrica Antonia
    Labanca, Caterina
    Mendicino, Francesco
    Lucia, Eugenio
    Olivito, Virginia
    Neri, Antonino
    Morabito, Fortunato
    Vigna, Ernesto
    Gentile, Massimo
    EXPERT OPINION ON PHARMACOTHERAPY, 2023, 24 (14) : 1537 - 1543
  • [27] Alemtuzumab in the Treatment of Chronic Lymphocytic Leukemia
    Tadeusz Robak
    BioDrugs, 2005, 19 : 9 - 22
  • [28] Advances in the treatment of chronic lymphocytic leukemia
    Lamanna N.
    Current Oncology Reports, 2005, 7 (5) : 333 - 338
  • [29] Lenalidomide in the treatment of chronic lymphocytic leukemia
    Itchaki, Gilad
    Brown, Jennifer R.
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2017, 26 (05) : 633 - 650
  • [30] New emerging therapies in the management of chronic lymphocytic leukemia
    Li, Xiao-Lin
    Zhang, Ci-Xian
    ONCOLOGY LETTERS, 2016, 12 (05) : 3051 - 3054